The partners will use Adaptive's ClonoSeq assay to assess minimal residual disease in several of Amgen's hematology drug development programs.
The award will fund optimization of the Hemopurifier exosome isolator, with an eye towards developing applications in cancer research and clinical care.
Exome sequencing and other molecular strategies led to a heterogeneous variant in the DNMT3A gene that appears to impact host epigenetic and immune features.
The new project will be the second stage of the QSkin study, which has documented the disease in 44,000 Australians and developed a melanoma risk predictor.
The blood-based test is designed to detect changes in levels of microRNAs that are enriched in specific brain regions affected by Alzheimer's disease.
PWNHealth will provide physician oversight and genetic counseling for Picture Genetics, a new line of three genetic tests from Fulgent aimed at consumers.
The firm saw steady growth in its research reagents and screening businesses, and a 155 percent revenue increase in its bioproduction unit.
Last week, GenomeWeb's readers were most interested in Illumina's suit challenging a patent awarded to Columbia University for NGS technology.
Interpace Diagnostics subsidiary Interpace BioPharma will perform services worldwide, while Genecast will offer the services in China.
The study will evaluate how Prolaris impacts prostate cancer treatment decisions, and how those decisions impact costs within UK's National Health Service.
As part of the shift, DNA.Land, which was run as an academic research project, will delete all data by the end of the month and ask customers to resubmit it.
The European companies aim to link individuals who have used direct-to-consumer genetic tests with clinical trials and other research programs.
Divesting the cord blood business will allow Natera to focus on its genetic testing business in reproductive health, oncology, and organ transplantation.
The team will use a combination of genomics, pathology, and computer modeling to identify potential new therapeutic targets of the disease.
The firm said that on Oct. 13 it will redeem all of its outstanding 5 percent unsecured notes due in 2021.
The Radiance platform uses laser force cytology technology to measure optical and fluidic forces within a microfluidic channel for cellular analysis.
Thermo Fisher Scientific said today that it plans to redeem two classes of senior notes later this month, with a total aggregate principal amount of $1.1 billion.
The Pleasanton, California-based single-cell sequencing firm said that net proceeds of the IPO will be approximately $357.5 million.
he lawsuit, filed on the eve of 10x's IPO, alleges that 10x's new Next GEM microfluidic chips infringe a patent exclusively licensed to Bio-Rad.
The test detects 20 common viruses and bacteria that cause upper respiratory infections using the firm's high-throughput, automated MDx-3000 instrument.
Machine learning and DNA methylation analyses helped distinguish between primary lung tumors and lung tumors stemming from head and neck cancer metastasis.
Researchers identified Streptococcus pyogenes isolates from a lineage dubbed M1UK that are predicted to produce higher-than-usual levels of a scarlet fever-associated toxin.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.